Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 19/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634834 | 0.93 | CHRM1 (0.53) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL14145633 | 0.87 | CHRM1 (0.56) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12131805 | 0.85 | CHRM1 (0.52) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL3003076 | 0.83 | CHRM1 (0.52) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL1574138 | 0.83 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL1116676 | 0.83 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12086312 | 0.83 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL1116674 | 0.83 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL15202971 | 0.83 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL1338719 | 0.83 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994323-B2 | Chromen-2-one derivatives | NEUROSEARCH A/S (DK) | 2011-08-09 | — | — | US | claimed |
| EP-2158200-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH AS (DK) | 2011-07-13 | — | — | EP | claimed |
| US-20100217002-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2010-08-26 | — | — | US | claimed |
| EP-2158200-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NeuroSearch A/S (DK) | 2010-03-03 | — | — | EP | claimed |
| WO-2008138854-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2008-11-20 | — | — | WO | claimed |
| US-8697691-B2 | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697691-B2 | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| US-7994323-B2 | Chromen-2-one derivatives | NEUROSEARCH A/S (DK) | 2011-08-09 | — | — | US | disclosed |
| WO-2011087812-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| EP-2158200-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH AS (DK) | 2011-07-13 | — | — | EP | disclosed |
| US-20100217002-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| EP-2158200-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NeuroSearch A/S (DK) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008138854-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2008-11-20 | — | — | WO | disclosed |
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | CHRM1 125/4885CHRM2 344/4885CHRM3 214/4885 |
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM2 2/4885CHRM3 5/4885 |
| US-20100217002-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | CBX2, CYP2J2, CDYL2 | CHRM1 630/4885CHRM2 677/4885CHRM3 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.